Vaxcyte launches $1 bln stock, convertible offerings
Vaxcyte is launching public offerings of $500 million in stock and pre-funded warrants, and $500 million in convertible bonds due October 2032. The company intends to use the proceeds to fund the clinical development of its pneumonia vaccine VAX-31 and its seasonal influenza vaccine.